Kristin C. Jensen
Stanford University
72 Papers
502 Citations
Kristin C. Jensen is an academic researcher from Stanford University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 34, co-authored 68 publications. Previous affiliations of Kristin C. Jensen include Veterans Health Administration & University of California, San Francisco.
Chat about Author
Papers
Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer
Anosheh Afghahi,Erna Forgó,Aya A. Mitani,Manisha Desai,Sushama Varma,Tina Seto,Joseph Rigdon,Kristin C. Jensen,Kristin C. Jensen,Megan L. Troxell,Scarlett Lin Gomez,Scarlett Lin Gomez,Amar K. Das,Amar K. Das,Andrew H. Beck,Allison W. Kurian,Robert B. West +16 more
TL;DR: CNAs have the potential to improve the identification of high-risk DCIS, defined by presence of concurrent IBC, and expanding and validating this approach in both additional cross-sectional and longitudinal cohorts may enable improved risk stratification and risk-appropriate treatment in DCIS.
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
M. Sharma,Andrew H. Beck,Jonathan Webster,Inigo Espinosa,Kelli Montgomery,S. Varma,M van de Rijn,Kristin C. Jensen,Kristin C. Jensen,Robert B. West,Robert B. West +10 more
TL;DR: First characterization of stromal signatures derived from a macrophage response and fibroblast expression signatures in DCIS find these signatures have significant clinicopathologic associations and tend to be conserved as the tumor progresses from DCIS to invasive breast cancer.
Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast.
C. Fasola,Jie Jane Chen,Kristin C. Jensen,Kristin C. Jensen,Kimberly H. Allison,Kathleen C. Horst +5 more
TL;DR: The findings support a recommendation for complete surgical excision of PLCIS when diagnosed on core needle biopsy (CNB), and of the 20 cases with PLCis alone on CNB, 6 were upgraded to invasive carcinoma or DCIS after final surgical excison.
Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
Mandy L. Y. Sin,Mandy L. Y. Sin,Kathleen E. Mach,Kathleen E. Mach,Rahul Sinha,Fan Wu,Dharati Trivedi,Dharati Trivedi,Emanuela Altobelli,Emanuela Altobelli,Kristin C. Jensen,Kristin C. Jensen,Debashis Sahoo,Ying Lu,Ying Lu,Joseph C. Liao,Joseph C. Liao +16 more
TL;DR: Urine-based molecular diagnostics using this three-marker signature could provide a valuable adjunct to cystoscopy and may lead to a reduction of unnecessary procedures for bladder cancer diagnosis.
'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.
Morgan Ballard,Florencia Jalikis,Gregor Krings,Rodney A. Schmidt,Yunn-Yi Chen,Mara H. Rendi,Suzanne M. Dintzis,Kristin C. Jensen,Robert B. West,Richard K. Sibley,Megan L. Troxell,Kimberly H. Allison +11 more
TL;DR: Results support the current classification scheme for HER2 FISH, with case-by-case correlation with additional clinical-pathologic factors when evaluating whether to offer HER2-targeted therapies in these non-classical cases.